Introduction {#s1}
============

During last decades, a cilium has emerged as a key player in numerous physiological and developmental processes. Ciliary dysfunction results in a broad range of clinical diseases limiting the quality of patient´s life even despite an appropriate therapy. Therefore, cilia have become an important focus of interest in respirology. The exact mechanisms responsible for their motility and regulation have been elucidated recently, and the involvement of cyclic nucleotide (cAMP, cGMP) signaling in amplifying the Ca^2+^-dependent movement of motile cilia has been confirmed as one of the most important ([@B111]; [@B48]). This explains why inhibition of phosphodiesterases (PDEs), enzymes responsible for degradation of cAMP and cGMP, represents one of the targets for pharmacological modulation ([@B64]) and improvement of ciliary dysfunction.

Cilia {#s2}
=====

Cilia are microtubule-based organelles that have diverse motility and sensory functions. Although nearly all of cilia possess sensing role and transmit extracellular signals into intracellular biochemical responses, only some of them are able to move.

Motile cilia perform rotary motion or create wave-like planar beating based on the presence or absence of a central pair of microtubules surrounded by nine microtubule doublets of axoneme. Rotary motion additionally requires the absence of radial spokes ([@B86]). Adenosine triphosphate (ATP) as a source of energy is essential for the ciliary motion during which dynein motor proteins generate sliding movement between adjacent microtubules. Motile cilia were primarily found on ciliated epithelium lining the respiratory tract, fallopian tubes, brain ventricles, and the spinal cord. Except of their involvement in motility, all motile cilia play also sensory functions ([@B4]; [@B93]; [@B56]; [@B104]; [@B85]).

Immotile cilia (known also as "primary cilia") act as sensory organelles of the cell, and their crucial role can be observed in various ciliopathies including retinal degeneration, anosmia, deafness, hepatobiliary, pancreatic cyst, and many others ([@B38]; [@B103]; [@B50]; [@B12]; [@B68]; [@B35]).

Cilia can be classified into four basic types ([**Figure 1**](#f1){ref-type="fig"}): motile cilia with a central pair of microtubules (9 + 2), motile cilia without a central pair of microtubules (9 + 0), non-motile cilia with a central pair of microtubules (9 + 2), and non-motile cilia with absent central pair of microtubules (9 + 0) ([@B22]).

![Structure of cilia viewed in cross-section and cilia distribution based on the motility in the body. Motile cilia with/without a central pair of microtubules (9 + 2/9+0), immotile cilia with/without a central pair of microtubules (9 + 2/9+0).](fphar-11-00609-g001){#f1}

Structure of Cilia {#s2_1}
------------------

Motile cilia of airway epithelial cells contain a central pair of single microtubules surrounded by nine peripheral microtubule pairs (9 + 2) and protein complexes necessary for ciliary beating, such as axonemal dynein arms and radial spokes ([@B100]). The dynein arms are generally classified into two distinct groups according to the number of heavy-chain motor units. The first group with the inner dynein arms is often situated along the axonemal lengths, although several "minor dyneins" were found near the ciliary base probably due to their role in bend initiation. The second group of the outer dynein arms is required to restart backward motion of cilium and change the ciliary beat pattern associated with increase of calcium levels in response to different signals ([@B46]). So, the change in the ciliary beat frequency (CBF) is dependent on the outer dyneins.

Normal ciliary ultrastructure can be visualized using a transmission electron microscopy (TEM). High-speed digital video analysis has improved measurement and quantification of CBF, while improvements in air--liquid interface culturing techniques have led to development of *in vitro* models to investigate mucociliary clearance.

Ciliar Motility {#s2_2}
---------------

The cilia of the airways beat in a highly coordinated and synchronized fashion across multiple ciliated cells. At the basal conditions the low CBF is dependent on the dynein ATPase activity of the axoneme with ability of cilia to increase it in the response to various stimuli ([@B58]). Calcium (Ca^2+^)--calmodulin complex could be considered as the key regulator of CBF linked with both nucleotides, cAMP (cyclic adenosine monophosphate) and cGMP (cyclic guanosine monophosphate), in the process of ciliary stimulation, although cAMP can also play a role in Ca^2+^-independent manner ([@B111]). In this cross-talk the cyclic nucleotides are essential for Ca^2+^ to be effective since disruption of nitric oxide (NO)--cGMP--protein kinase (PK) G pathway at any of the steps in the presence of high Ca^2+^ concentration eliminates its action ([@B84]). Ca^2+^ is generally released from intracellular sources by inositol-3-phosphate (IP~3~) following stimulation of certain membrane receptors (e.g., purinergic P2Y2, cholinergic M~1~ and M~3~) or is transported from extracellular space *via* ion channels that mediate influx of Ca^2+^ to the ciliary cells ([@B84]).

Ciliary response to "second messengers" is usually biphasic. During the initial phase the rise in CBF mediated *via* muscarinic receptors is Ca^2+^--calmodulin-dependent and mainly regulated by PKG. The second phase of CBF enhancement is induced by acetylcholine (Ach) with a sustained moderately elevated CBF, requiring PKG activation. However, this phase is controlled predominantly by axonemal PKA in a Ca2+-independent manner ([@B79]; [@B53]; [@B51]; [@B111]; [@B81]). Most enzymes and precursors involved in the ciliary motility are located at the base of the ciliary axoneme close to their site of action targeting phosphorylation and efficient regulation of the ciliary beating ([@B91]).

CBF can be considered as one of the crucial factors determining the rate of mucociliary clearance in daily life since even small frequency reduction (beats/s) may have clinical significance when considering clearance of secretions over hours. Furthermore, despite the normal CBF, the efficacy of mucociliary clearance is dependent also on the proper ciliary beat pattern. This is well documented in patients with primary ciliary dyskinesia (PCD) ([@B42]).

Cilia in Mucociliary Clearance {#s2_3}
------------------------------

Mucociliary clearance belongs to the group of defense mechanisms in the airways. In pathological conditions associated with CBF slowing (e.g., respiratory infection), the cough and the other antibacterial defense mechanisms can temporarily substitute it ([@B24]; [@B5]). Therefore, drug combinations of cough suppressants and agents with negative effects on the ciliary beating in the airways could be considered as unsuitable with strong clinical significance, as they negatively influence also reserve defense mechanism. Similarly, less risk for exacerbations of chronic bronchitis or chronic obstructive pulmonary disease (COPD) has been recently confirmed in patients taking mucolytics probably due to reduced mucus viscosity making it easier to expectorate ([@B74]). Mucolytics provide also additional direct cilio-stimulatory and bronchodilator effects without impact on the cough sensitivity, anti-inflammatory ([@B72]; [@B25]), antioxidant ([@B62]) or immunomodulatory properties, in addition to the ability to reduce bacterial adhesiveness ([@B11], [@B71]).

The overall effect of mucociliary clearance is dependent on the proper ciliary function determined by the ciliary beat frequency, on the ciliary pattern, and on the optimal airway surface hydration state involving the presence of an airway surface layer (ASL). ASL is responsible for mechanical trapping of inhaled particles and pathogens by mucous component and for facilitating ciliary beating in presence of the periciliary layer. These facts have been confirmed in primary and secondary ciliary dyskinesia or cystic fibrosis. The former is related to the ciliary dysfunction as a consequence of defects in the ciliary structure based on the genetic mutations or inflammatory mediators and pH of the cilia environment, respectively ([@B76]; [@B8]; [@B16]; [@B32]; [@B36]). The latter is caused by impaired epithelium hydration with high mucus viscosity as a result of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Over time, ciliary dysfunction leads to recurrent respiratory infections and consecutive decline in lung functions leading to decreased quality of patients' life.

Secondary ciliary dyskinesia includes acquired defects of ciliary movement, which can be caused by viral or bacterial infection or by air pollutants. This may be evident in lung diseases such as bronchial asthma, and COPD. However, a direct relationship between ciliary dysfunction with ultrastructural abnormalities and disease severity was observed only in asthma subjects ([@B94]). In COPD studies, controversial results were confirmed with the CBF discrepancy in response to cigarette smoke ([@B112]; [@B17], [@B108]; [@B109]). Different CBF values related to the cilia length shortening due to autophagic mechanisms were also found by some researchers ([@B52]). Furthermore, the uncoordinated cilia function is not typical for moderate to severe stages of COPD, and the number of non-ciliated cells well correlates with the severity of the disease ([@B108]).

Chronic Obstructive Pulmonary Disease {#s3}
=====================================

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease associated with chronic inflammation of the lung parenchyma and peripheral airways. This leads to persistent respiratory symptoms and progressive airflow limitation usually caused by significant exposure to tobacco smoke and airborne pollutants ([@B31]).

The pharmacotherapy of COPD is strictly individualized based on the disease severity, drug efficacy, drug tolerance, patient preferences, comorbidities, and potential drug interactions. Bronchodilators and anti-inflammatory medications are one of the cornerstones of COPD management. They reduce clinical symptoms, prevent the development of airflow limitation, lower the risk and severity of exacerbations, and improve the patients' quality of life and exercise tolerance. Despite the relative effectivity of these agents, severe or very severe stages of the disease (FEV1 post-bronchodilator less than 50% predicted) can sometimes developed probably due to progression of inflammatory process.

Long-term inhaled treatment with corticosteroids (CS) in association with long-acting beta~2~ agonists (LABA) reduce but do not eliminate acute exacerbations of COPD. Methylxanthines have been accepted as being effective drugs for the treatment of COPD possessing both anti-inflammatory and bronchodilator activity in the same molecule. But findings about their non-selective mechanisms responsible for their relatively unfavourable safety profile have led to the development of novel therapeutic drugs with more selective properties.

PDE/PDE Inhibitors and COPD {#s3_1}
---------------------------

The discovery of phosphodiesterase isoenzymes (PDEs) along with increased understanding of their different function based on the tissue/cell specificity was a driving force for the development of PDE selective inhibitors for the treatment of various diseases including COPD. Up-to-date, 11 isoenzymes families of PDEs have been recognized (PDE1 - PDE11), of which PDE3 and PDE4 are the major cAMP-hydrolyzing enzymes identified in the smooth muscle. They are involved in the airway smooth muscle tone regulation and inflammatory cell activity. PDE1 and PDE5 are responsible for the cGMP-hydrolytic activity in airway and vascular smooth muscle ([@B95]).

Roflumilast, the first selective PDE4 inhibitor approved for the therapy of COPD, is an anti-inflammatory agent that improves lung function in patients with moderate to severe COPD and reduces the risk of moderate to severe exacerbations when add on to bronchodilators (SABA, LABA), or inhaled CS. Although it is generally well tolerated, systemic effect of the drug is associated with the risk of diarrhea, nausea, weight loss, headaches, and suicide limiting its use and inhaled form if this drug with more favorable safety profile would be of benefit.

It is well known that most recommended drugs for COPD are given by inhalational route ([@B31]). It provides several significant advantages over systemic administration: lower effective dose than with systemic delivery, higher concentration of the drug reached in the airways, direct local delivery of the drug avoiding the systemic circulation and first pass effect in the liver. The benefits of local administration include fewer and less severe adverse effects, more selective actions, and direct interaction of the drug with ciliary epithelium. This makes the mucociliary clearance more efficient in removing of excess mucous from the lungs during pathological conditions, especially in case the drug has cilio-stimulatory properties.

Thus, mucus hypersecretion and chronic productive cough as the two characteristic features of COPD suggest the airway ciliary dysfunction and indicate the need for improvement of ciliary motility in the severe stages of this disease. At present, there are no specific therapies available to correct the ciliary dysfunction and the empiric treatment helps only to manage the consequences of dysfunctional cilia. Therefore, inhalational route of administration and focusing on mechanisms ameliorating the ciliary beating frequency (e.g., increased intracellular concentrations of cyclic nucleotides caused by PDE inhibition) might be of huge benefit ([@B61]; [@B49]; [@B114]).

PDE and Ciliary Motility {#s4}
========================

The activity of PDE proteins is dependent on cell type. In the human airway epithelial cells PDE4 activity is predominantly expressed in addition to lesser PDE1, PDE3, and PDE5 activity ([**Table 1**](#T1){ref-type="table"}) ([@B107]). The airway smooth muscle (ASM) human cells express both PDE3 and PDE4 enzymes ([@B7]). As described above, activity of PDE leads to relatively flexible changes in intracellular cAMP concentrations, which are involved in direct modulation of calcium mediated contractions of microtubular apparatus. As described in an older study by [@B92], the phosphodiesterase inhibition by 3-isobutyl-1-methylxanthine and the adenylate cyclase stimulation by forskolin led to increase in CBF in a dose-dependent manner and were accompanied by the increases in intracellular concentrations of cAMP. These results suggest that cAMP may accelerate mucociliary clearance through the activation of ciliary motility and that intracellular cAMP levels appear to be an important determinant for the lung mucociliary transport functions ([@B92]). Similar results were observed by [@B80], who described dose-dependent, albeit similar and simultaneous increases in cAMP and ciliary beat frequency caused by forskolin administration on human airway epithelial cells. Therefore, an inhibition of PDEs, either non-selective or selective to mostly expressed isoforms in the airways, might be potentially useful in the modulation of CBF, either directly by changing the cAMP levels in cilia, or indirectly by influencing the allergic or other inflammation ([@B7]).

###### 

PDE families expressed in ciliary epithelia with their selective inhibitors and references of papers describing modulatory effects on ciliary motility.

  PDE family   Preference to cAMP or cGMP   Selective inhibitor     Ciliary motility modulation
  ------------ ---------------------------- ----------------------- -----------------------------
  PDE1A        Both                         8MmIBMX                 [@B48]
  PDE3         Both                         Milrinone               [@B15]
  PDE4         cAMP                         Rolipram, Roflumilast   [@B15]; [@B105]; [@B61]
  PDE5         cGMP                         Zaprinast               [@B15]

Chronic treatment with PDE inhibitors seems to have stronger effect on the ciliary beating since they do not directly increase the generation of cAMP, but decrease its breakdown. Therefore, their stronger action is expected in more progressed disease stages.

Non-Selective PDE Inhibitors {#s4_1}
----------------------------

There are several older studies focused on involvement of cyclic nucleotides in sperm ciliary impairment. Non-selective inhibitors of PDEs produce marked stimulation of cAMP dependent motility, but not all of them have equal efficacy. Caffeine was demonstrated to have a dose-dependent action with benefit at low to moderate doses in some human studies, whilst high-dose led to detrimental effects ([@B55]; [@B67]; [@B39]). Pentoxifylline (PTX), a potent vasodilating agent recommended for the treatment of leg pain caused by chronic occlusive arterial disease of the limbs, was studied as an artificial sperm movement enhancer ([@B77]; [@B1]). Its effect on sperm motility was confirmed in several *in vivo* studies with significantly increased sperm motility in men with oligoasthenoteratozoospermia (OAT) or *in vitro* studies during a vitrification program without adverse effects on sperm DNA or chromatin integrity ([@B90]; [@B66]; [@B69]). However, the results of PTX treatment in terms of assisted reproductive technologies outcomes are not consistent. This is due to the treatment failure of PTX in improvement of ejaculate parameters including the motility ([@B59]). In *in vitro* conditions, PTX significantly enhanced the viability of sperm of infertile OAT males with no significant effect on its motility ([@B29]).

Theophylline has been confirmed to have a protective impact on sperm motility during freezing procedures ([@B21]; [@B34]). However, teratogenic potential of methylxanthines is a limiting factor of their clinical use in improving sperm motility and fertilizing ability ([@B28]; [@B96]; [@B26]; [@B6]). Moreover narrow therapeutic index and non-selective mechanism of action with high risk of systemic adverse effects favors other drugs over methylxanthines.

Similarly to sperm cilia, tracheal ciliary epithelium is controlled by intracellular cAMP levels. In a recent animal study was confirmed that the ciliary beat frequency in tracheal epithelial cells is significantly higher, when ovalbumin-sensitized guinea pigs were treated with systemic theophylline at the dose of 10 mg/kg/day ([@B45]). This suggests direct involvement of PDE inhibition in ameliorating the impaired defense mechanisms caused by sensitization and challenging the animals with ovalbumin, used to mimic the asthma-like conditions (airway hyperresponsiveness associated with eosinophilic inflammation). However, this study did not reveal the exact involvement of PDE inhibition in direct influence on cilia or indirect effects caused by anti-inflammatory and immunomodulation action of theophylline. Therefore, selective PDE inhibitors responsible for inhibiting single PDE isoforms expressed in ciliary epithelial cells need to be tested.

Selective PDE1 Inhibitors {#s4_2}
-------------------------

The experimental study of [@B48] has recently confirmed the expression of PDE1A by immune-electron microscopy methods in the cilia and the cell body of lung airway ciliary cells. Ca^2+^/calmodulin-dependent PDE1A was detected on the nine doublet tubules ring and outside the ring in the lung airway cilium, where the outer dynein arm functions. PDE1A modulates CBF in lung cells in a Ca^2+^ dependent manner ([**Figures 2A, B**](#f2){ref-type="fig"}). PDE1A inhibition induced by low intracellular Ca^2+^ enhances CBF due to cAMP accumulation ([@B49]).

![**(A)**: CBF down-regulation by PDE1A in presence of Ca^2+^ ions. **(B)** Involvement of PDE1A inhibition in CBF increase (CBF, ciliary beat frequency; PDE1A, phosphodiesterase 1A; cAMP, cyclic 3′, 5′-adenosine monophosphate; Orai, calcium release-activated calcium channel involved in T-lymphocytes activation; STIM1, stromal interaction molecule 1 - calcium sensor in endoplasmic reticulum).](fphar-11-00609-g002){#f2}

PDE1C isoform was found in the mitochondria of cell body, but not in the cilia. Similar results were observed in motile sperms of mice ([@B99]) as well as in human spermatozoa ([@B54]), where a new isoform of PDE1A was detected.

Despite of these observations, there is currently only limited data about efficacy of PDE1 inhibitors in respiratory diseases. Vinpocetin, a selective PDE1 inhibitor used for increasing learning and memory due to its vasodilating effect in cerebral circulation caused by cGMP increase, was shown to have mild antitussive and bronchodilating action in healthy and ovalbumin sensitized guinea pigs ([@B63]). However, no information about its effects on CBF is available.

Selective PDE4 Inhibitors {#s4_3}
-------------------------

As mentioned above, the airway smooth muscle (ASM) human cells as well as epithelial cells express PDE4 enzymes ([@B7]; [@B65]). This is consistent with the findings of *in vitro* experiments showing that ASM human cells are primarily sensitive to cilostamid (PDE3 inhibitor), while both ASM cells and human non-polarized bronchial epithelial (16HBE 14o) cells are responding to PDE4 inhibition by roflumilast. Moreover, selective PDE4 inhibition was found to induce an effective reversion in the CBF down-regulation induced by cigarette exposure in *ex vivo* conditions under which expression of both PDE3 and PDE4 enzymes is dominant ([@B61]; [@B114]). Furthermore, LABA enables roflumilast (selective PDE4 inhibitor) ability to stimulate CBF in cigarette smoke exposed cells, while roflumilast itself does it only in limited manner, as demonstrated by [@B83]. They showed that roflumilast can rescue smoke-induced mucociliary dysfunction by reversing decreased cystic fibrosis transmembrane conductance regulator (CFTR) activity, augmenting airway surface liquid volume, and stimulating CBF, the latter particularly in combination with formoterol. Of the 11 PDE families, PDE3 and PDE4 have been shown to regulate cAMP-stimulated CFTR, thus PDE4 inhibitors can potentiate the effect of CFTR correctors due to regulation of ion and water transport across epithelia ([@B10]). [@B106] examined 229 substances based on their effects on CBF. Among PDE4 inhibitors, roflumilast, roflumilast-N-oxide, and ibudilast increased CBF, whereas theophylline as a non-selective PDE inhibitor decreased it, probably due to antagonistic action on adenosine A~2B~ receptors ([@B3]). Furthermore, most of tested glucocorticosteroids and anticholinergics led to decrease of CBF, suggesting a benefit of co-administration of PDE4 inhibitors with these groups of drugs to prevent worsening of expectoration in COPD patients ([@B106]).

Dual PDE3/4 Inhibitors {#s4_4}
----------------------

Dual PDE3/4 inhibitors represent another strategy of potential pharmaco-therapeutic agents for the treatment of respiratory diseases because of their mixed bronchodilator/anti-inflammatory effects and enhanced efficacy in a single molecule compared to inhibition of only PDE3 or PDE4. Their benefit involves efficacy both in acute and long-lasting bronchodilation along with anti-inflammatory properties ([@B88]). Clinical use of a inhaled bifunctional PDE3/4 inhibitor (ensifentrine/RPL554) in respiratory diseases is currently limited to a few studies, including bronchial asthma, in which mixed PDE3/4 inhibition has a beneficial effect comparable with salbutamol but avoiding characteristic systemic adverse effects of beta~2~ agonists ([@B9]). In a recent study, RPL554 increased CBF in primary human bronchial epithelial cells, suggesting that RPL554 may increase mucociliary clearance through stimulation of CFTR and increasing CBF and, thus, could provide a novel therapeutic option for, e.g., cystic fibrosis ([@B97]). Ensifentrine has recently entered clinical phase II of drug testing, in order to demonstrate its benefits as an add-on therapy in patients for the treatment of acute exacerbations of COPD or for the regular maintenance treatment of patients either alone, or on top of existing drug classes ([@B13]). However, at present the most intriguing perspective is linked to its possible use in the treatment of cystic fibrosis, also considering the lack of valid therapeutic options for this disease ([@B14]).

Other Drugs with Cilio-Stimulatory Properties (Mucokinetics) Used for COPD and Asthma Therapy {#s5}
=============================================================================================

Beta~2~ Agonists {#s5_1}
----------------

The mucokinetic agents may influence mucociliary clearance directly by acting on the cilia. There is evidence that bronchodilators SABA and LABA improve beating kinematics *via* increase in the CBF in *in vitro* conditions ([@B19]; [@B44]; [@B27]; [@B72]). However, in patients with moderate and severe bronchial asthma, the CBF significantly declines despite treatment with long-acting bronchodilators ([@B94]). The question is to what extent the CBF is influenced by direct effect of the drug in conditions of chronic inflammation and epithelium remodeling. [@B49] demonstrated that increase in the intracellular Ca^2+^ concentration stimulates PDE1A leading to degradation of cAMP and to suppression of the procaterol-stimulated CBF increase. Ca^2+^ influx represents a motor for PDE1A most likely *via* calcium release-activated ion channels (CRAC), whilst Ca^2+^ released from intracellular stores plays only little or no role ([@B111]; [@B33]; [@B43]). CRAC ion channels belong to the group of store operated ion channels and become active when Ca^2+^ intracellular sources are depleted. It seems that CRAC channel opening is involved in a dual mechanism: extracellular Ca^2+^ enables the refilling of endoplasmic reticulum Ca^2+^ stores ([@B75]) with Ca^2+^-mediated cilio-stimulatory impact, but also links with cAMP-dependent PDE1A activities. The overall change in ciliary beating is dependent on the balance of Ca^2+-^signal and cAMP-signal ([@B49]) with dominant response of the latter in pathological conditions due to the cAMP breakdown ([**Figure 2A**](#f2){ref-type="fig"}). This hypothesis has been confirmed in our experiments with significant decrease in the CBF during physiological conditions, when CRAC channel blocker was used, whilst different ciliary response seen in airway allergic inflammation in ovalbumin-sensitized guinea pigs ([@B43]). Upregulation of STIM1 and Orai1 proteins, the molecular components of CRAC ion channels in inflammatory conditions can explain our findings ([@B89]). Moreover, high levels of ATP associated with tissue damage or inflammation provides a substrate for soluble adenylyl cyclase (sAC) and generation of more cAMP for being PDE active to slow down the ciliary beating. This explains potential benefit of selective PDE1A inhibition in increasing the CBF ([**Figure 2B**](#f2){ref-type="fig"}). Furthermore, the closing connexin/pannexin hemichannels that release ATP and decreasing intracellular Ca^2+^ levels may also suppress the CBF ([@B82]; [@B87]; [@B20]; [@B113]).

Similar results were obtained in *in vitro* studies modelling COPD; the increase in the CBF induced by beta~2~ agonist was abolished by up-regulation of IL-8 in response to cigarette smoke. Thus, it is likely that smokers may be more resistant to the cilio-stimulatory effects of beta~2~ agonists ([@B2]).

Anticholinergic Drugs {#s5_2}
---------------------

Although it is generally believed that acetylcholine increases CBF *via* muscarinic receptors ([@B101]; [@B78]; [@B110]), anticholinergic agents exert cilio-inhibitory effects of different intensities in experimental studies ([@B73]; [@B102]). Muscarinic receptor antagonists provide benefit in COPD by blocking cholinergic tone and bronchodilation; however, there is no clinical evidence about their effect on the ciliary beating in such conditions. M~3~ receptors are involved in the control of ciliary beat frequency, whereas M~2~ receptors play an opposite role and prevent cilia-excitation initiated by M~1~ receptors as well as by non-muscarinic stimuli such as ATP. However, M~2~ receptors are not detectable in the epithelial cells and are found only in neighboring cells ([@B47]).

Glucocorticosteroids {#s5_3}
--------------------

In animal studies, chronic inhalation of budesonide significantly lowered the CBF using a 21-days model of ovalbumin-induced allergic airway inflammation, whilst non-significant changes of this parameter have been documented in the 28-days model ([@B70]) despite decreased level of IL-13 determined in bronchoalveolar lavage fluid and significant anti-inflammatory effect. In patients with COPD, acute inhalation of beclomethasone dipropionate did not affect mucociliary clearance rates ([@B23]; [@B37]). There are no studies and data on the long-term effects of chronic therapy with corticosteroids on the ciliary beat frequency and mucociliary clearance. However, a long-term inhalation of steroids in severe asthmatic patients leads to reduced epithelium damage and decreased non-ciliated areas in the ciliated epithelium ([@B57]). This may be consistent with the experimental finding that cilio-stimulatory effects of LABA increase in presence of inhaled corticosteroids and the fact that ICS-LABA therapy significantly reduced the rate of exacerbations ([@B70]; [@B31]; [@B31]).

Antileukotriens {#s5_4}
---------------

Leukotrienes C~4~ and D~4~ as lipid mediators (products of arachidonic acid degradation by 5-lipooxygenase) increase the ciliary beat frequency in human upper airway mucosa *in vitro* ([@B18]). Moreover, experimental findings suggest that LTD~4~ exerts cilio-excitatory effects in human, guinea pig, and rat respiratory mucosa with impaired cilia orientation and mucus production ([@B41]).

Leukotriene modifiers could contribute to cilio-modulatory effect due to both time- and dose- dependent cilio-stimulatory effect of montelukast in human sinonasal epithelial cultures ([@B98]); however, these experiments have not been yet performed in inflammatory conditions.

Drug Excipients and the Ciliary Beating Frequency {#s5_5}
-------------------------------------------------

The cilio-inhibitory or cilio-static effect of preservatives and absorption enhancers used as drug excipients should also be taken in account. Despite their effectiveness in drug absorption and prevention of microbial contamination, they may interfere with mucociliary clearance and ciliary function ([@B60]; [@B40]).

Conclusions {#s6}
===========

Airway epithelial PDE isoforms could be considered as important targets for the development of new inhaled mucokinetic agents. Their inhibition represents a viable therapeutic approach to enhance mucociliary clearance in respiratory diseases. The major mechanisms involved in an overall improvement of mucociliary clearance in respiratory disease due to PDE1, PDE4 or PDE3/4 inhibitors include:

-   increase in the CBF to allow a removal of mucus more effectively from the lungs (PDE1, PDE4, PDE3/4 inhibitors);

-   better epithelium hydration lowering the mucus viscosity (PDE4, PDE3/4 inhibitors);

-   anti-inflammatory effect (PDE4 and PDE3/4 inhibitors);

-   bronchodilator effects (PDE3, PDE3/4 inhibitors);

-   relatively few systemic adverse effects when delivered *via* the inhaled route.

Furthermore, PDE1A inhibitors potentiate the cilia-stimulatory effects of beta~2~ agonist mediated by cAMP accumulation, whilst PDE4 inhibitors become effective in the presence of LABA to stimulate ciliary beating. This makes the mucociliary clearance in pathological airway conditions more effective.

Dual PDE3/4 inhibitors could provide additional benefits and show more rapid response when taken with beta~2~ agonist; however, their cilia-stimulatory effect is probably mediated predominantly by PDE4 inhibition.

In summary, PDE inhibitors besides their anti-inflammatory and bronchodilator properties can prevent recurrent infection, persistent inflammation, and decline in lung functions *via* direct cilia-stimulatory response, when cilia dysfunction in lung diseases has developed. Further research is required to provide evidence of the effectiveness and feasibility of the inhaled selective or bifunctional PDE inhibitors with respect to their cilia-modulating properties.
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